TWD 91.2
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 373.87 Million TWD | 10.04% |
2022 | 339.75 Million TWD | 9.2% |
2021 | 311.13 Million TWD | -17.11% |
2020 | 375.34 Million TWD | -14.96% |
2019 | 441.36 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 461.01 Million TWD | 23.31% |
2024 Q2 | 461.01 Million TWD | 0.0% |
2023 Q3 | 373.87 Million TWD | -28.79% |
2023 Q4 | 373.87 Million TWD | 0.0% |
2023 FY | 373.87 Million TWD | 10.04% |
2023 Q2 | 524.99 Million TWD | 0.0% |
2023 Q1 | 524.99 Million TWD | 54.52% |
2022 Q3 | 339.75 Million TWD | 0.0% |
2022 Q4 | 339.75 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 58.92% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -32.327% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 36.63% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 88.902% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 89.694% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 94.377% |
Center Laboratories, Inc. | 6.78 Billion TWD | 94.49% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -132.146% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 58.094% |
InnoPharmax Inc. | 48.64 Million TWD | -668.515% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -16.475% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 20.936% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 51.183% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 39.398% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -33.108% |
UniPharma Co., Ltd. | 37.4 Million TWD | -899.639% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 63.177% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -391.365% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -651.946% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -243.787% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -179.792% |